Skip to main content
SkinCited

Lactobacillus rhamnosus के लिए Eczema (Atopic Dermatitis)

B संबंधित साक्ष्य कम से कम एक यादृच्छिक परीक्षण इसका समर्थन करता है, जिसके परिणाम अधिकतर सुसंगत हैं।

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u0026condition\u003Deczema\u002Datopic\u002Ddermatitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

निष्कर्ष

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

Key Study Findings

Review
Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
Dose: None बनाम: None Outcome: Diarrhea, colic, allergy, atopic dermatitis प्रभाव: None None

जनसंख्या: Pediatric patients

Randomized Controlled Trial
[Effectiveness and safety of probiotics in children on the basis of clinical trials].
Dose: None बनाम: None Outcome: diarrhea प्रभाव: None None

जनसंख्या: None

Key Statistics

20

अध्ययन

3500

प्रतिभागी

Positive

B

ग्रेड

Referenced Papers

Archivos argentinos de … 2022 23 उद्धरण
Medycyna wieku rozwojowego 2012 1 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:
1-10 billion CFU/day
atopicdermatitis:
10 billion CFU/day L. rhamnosus GG

अधिकतम सीमा: Not established; generally well-tolerated at doses up to 100 billion CFU/day

अनुसंधान में अध्ययन की गई खुराकें

खुराक अवधि प्रभाव N
None -- Positive --
None -- Positive --

सेवन का सर्वोत्तम समय: Before or with meals; some studies suggest empty stomach

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

  • Mild gas or bloating (temporary, during initial use)
  • Rare infections in severely immunocompromised individuals

ज्ञात अंतःक्रियाएँ

  • Immunosuppressants (theoretical concern — live bacteria)
  • Antibiotics (may reduce probiotic viability — separate by 2+ hours)

सहनीय अधिकतम सेवन: Not established; generally well-tolerated at doses up to 100 billion CFU/day

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Lactobacillus rhamnosus help with Eczema (Atopic Dermatitis)?
Based on 20 studies with 3,500 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus may support Eczema (Atopic Dermatitis) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus should I take for Eczema (Atopic Dermatitis)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus?
Reported side effects may include Mild gas or bloating (temporary, during initial use), Rare infections in severely immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus and Eczema (Atopic Dermatitis)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 3,500 total participants. The overall direction of effect is positive.

इसके लिए अन्य सामग्री Eczema (Atopic Dermatitis)

Lactobacillus rhamnosus अन्य स्वास्थ्य स्थितियों के लिए

References

  1. [1] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  2. [2] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।